Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era

Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era

BackgroundDiffuse large B-cell lymphoma (DLBCL) is an aggressive and the most common type of non-Hodgkin lymphoma (NHL). The clinical use of rituximab has improved the treatment response and survival of patients with DLBCL. The introduction of rituximab biosimilar into healthcare system has helped i...

Full description

Bibliographic Details
Main Authors: Reena Nair, Gull Mohammad Bhat, Narendra Agrawal, Manju Sengar, Pankaj Malhotra, Soniya Nityanand, Chitra Lele, Pramod Reddy, Suresh Kankanwadi, Narendra Maharaj
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
rituximab
real world
DLBCL
biosimilar
Reditux™
Ristova® Rituximab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1248723/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1248723/full

Similar Items